Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26412865 | 1.00 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL20467873 | 0.95 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL21413563 | 0.95 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL17722898 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL21780990 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL19709072 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL17815262 | 0.94 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL25009079 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL24477218 | 0.93 | SIRT2 (0.42) | SIRT2SIRT1SIRT5SIRT3HTT | |
| SCHEMBL22698585 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022006327-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | SIRT2 886/4885SIRT1 859/4885SIRT5 971/4885 |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | SIRT2 1593/4885SIRT1 1444/4885SIRT5 1462/4885 |
| US-20190169165-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | SIRT2 886/4885SIRT1 859/4885SIRT5 971/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | SIRT2 2353/4885SIRT1 2590/4885SIRT5 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.